THE ROLE OF BRAIN NATRIURETIC PEPTIDE (BNP) AND NT-PRO- BRAIN NATRIURETIC PEPTIDE (NT-PRO-BNP) IN CARDIAC FAILURE DIAGNOSTIC AMONG PATIENT WITH ESRD
Abstract
The role of BNP and NT-pro-BNP in cardiac failure diagnostic in general population was established. But patients with end-stage renal disease (ESRD) have elevated levels of natriuretic peptides in basic. Prognostic value of these peptides in ESRD population was unknown. Recent studies have shown that BNP and NT-pro-BNP are good predictors of all cause mortality and cardio-vascular diseases among patients with ESRD, but the cut-off value of natriuretic peptides is main theme of discussion.
Downloads
References
Селезньова І. Б. NT-pro-BNP, як маркер залишкової функції нирок у хворих з ХХН V стадії, що отримують нирковозамісну терапію методом гемодіалізу / І. Б. Селезньова // Український журнал нефрології та діалізу. – 2010. - № 1(25). – С. 41-43.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008.The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology / K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson et al. // European Heart Journal – 2008. - № 29. – Р. 2388–2442
Anwaruddin S. Renal Function, Congestive Heart Failure, and Amino-Terminal Pro-Brain Natriuretic Peptide Measurement. Results From the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study / S. Anwaruddin, D. M. Lloyd-Jones, A. Baggish, A.l Chen et al. // J Am Coll Cardiol. – 2006. - № 47. – Р. 91-97.
Chazot C. Fluid overload correction and cardiac history influence brain natriuretic peptide evolution in incident haemodialysis patients / C. Chazot , C. Vo-Van , E. Zaoui , T. Vanel et al. // Nephrol Dial Transplant. – 2011. – Vol. 26, № 8. – Р. 2630-2634.
Cowie M. R. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care / M. R. Cowie, A. D. Struthers, D. A. Wood , A. J. Coats et al. // Lancet. – 1997. - № 350. – Р. 1349–1353.
Dao Q. Utility of Btype natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting / Q. Dao, P. Krishnaswamy, R. Kazanegra, A. Harrison et al. // J Am Coll Cardiol. – 2001. – № 37. – Р. 379–385.
Davis M. Plasma brain natriuretic peptide in assessment of acute dyspnoea/ M. Davis, E. A. Espiner, T. Yandle, G. Richards et al. // Lancet -1994. - № 343. – Р. 440–444.
deFilippi CR. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis / C.R. deFilippi , J.C. Fink , C.M. Nass et al. // Am J Kidney Dis – 2005.
– Vol. 46. – P. 35–44.
Goto T. Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis / T. Goto , H. Takase , T. Toriyama , T. Sugiura , Y. Kurita et al. // Nephron. - 2002. – Vol. 92, № 3. – Р. 610-615.
Hobbs F. D. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: Cohort study in representative and high risk community populations / F. D. Hobbs , R. C. Davis , A. K. Roalfe , R. Hare et al. // BMJ. – 2002. - № 324. – Р. 1498.
Heublein D. M. Immunoreactivity and Guanosine 3′,5′-Cyclic Monophosphate Activating Actions of Various Molecular Forms of Human B-Type Natriuretic Peptide / Heublein D. M., Huntley B. K, Boerrigter G., Cataliottі A. et al. // Hypertension – 2007. - № 49. – Р. 1114-1119.
Hunt P. J. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT- PROBNP): A new marker of cardiac impairment / P. J. Hunt, A. M. Richards, M. G. Nicholls , T. G. Yandle et al. // Clin Endocrinol (Oxf). – 1997. - № 47. – Р. 287–296.
Januzzi J. L. Jr. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study/ J. L. Januzzi Jr., C. A.Camargo, S. Anwaruddin , A. L. Baggish et al. // Am J Cardiol. – 2005. - № 95. – Р. 948–954.
Khan I. A. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients / I. A. Khan, J. Fink, C. Nass, H. Chen et al. // Am J Cardiol – 2006. – Vol. 97. – P. 1530–1534.
Liu H. Elevation of B-type natriuretic peptide is a sensitive marker of left ventricular diastolic dysfunction in patients with maintenance haemodialysis/ H. Liu , Y. Z. Zhang , M. Gao , B. C. Liu // Biomarkers. – 2010. – Vol. 15, № 6 – P. 533-537.
Logeart D. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure / D. Logeart, G. Thabut, P. Jourdain, C. Chavelas et al. // J Am Coll Cardiol – 2004. – Vol. 43. – P. 635-641.
Madsen L. H. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis / L. H. Madsen , S. Ladefoged, P. Corell, M. Schou et a. // Kidney Int. – 2007. – Vol. 71. – P. 548– 554.
Maisel A. S. Rapid measurement of B-type natriuretic riuretic peptide in the emergency diagnosis of heart failure/ A. S. Maisel , P. Krishnaswamy, R. M. Nowak, J. Mc-Cord et al. // N Engl J Med. – 2002. - № 347. – Р. 161–167.
Masson S. Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure / S. Masson, T. Vago, G. Baldi, M. Salio et al. / Clin Chem Lab Med – 2002. - № 40. – Р. 761–763.
Matayoshi T. Brain natriuretic peptide in hemodialysis patients: predictive value for hemodynamic change during hemodialysis and cardiac function / T. Matayoshi , T. Kato, H. Nakahama , H. Nakata et al. // Am J Nephrol. – 2008. – Vol. 28, № 1. – Р. 122-127.
McFarlane S. I. Role of the Natriuretic Peptide System in Cardiorenal Protection/ S. I. McFarlane, N. Winer, J. R. Sowers // Arch Intern Med. – 2003. – Vol. 163, № 22. – Р. 2696-2704.
Palazzuoli A. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure/ A. Palazzuoli, M. Gallotta, I. Quatrini, R. Nuti // Vasc Health Risk Manag. – 2010. - № 6. – Р. 411–418.
Plantinga L. C. Attainment of clinical performance targets and improvement in clinical outcomes and resource use in hemodialysis care: a prospective cohort study / L. C. Plantinga, N. E. Fink, B. G. Jaar, J. H. Sadler et al. // BMC Health Serv Res. – 2007. - Vol. 7. – P. 5.
Sakuma M. Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population / M. Sakuma, M. Nakamura, F. Tanaka, T. Onoda et al. // Circulation Journal. – 2010. – Vol. 74(4).
– P. 792-797.
Selim G. Brain Natriuretic Peptide between Traditional and Nontraditional Risk Factors in Hemodialysis Patients: Analysis of Cardiovascular Mortality in a Two-Year Follow-Up / G. Selim, O. Stojceva-Taneva, G. Spasovski, L. Georgievska- Ismail et al // Nephron Clin Pract. – 2011. – Vol. 119, № 2. – Р. 162-170.
Sharma R. Raised plasma N-terminal pro-Btype natriuretic peptide concentrations predict mortality and cardiac disease in endstage renal disease/ R. Sharma, D. C. Gaze, D. Pellerin, R. L. Mehta et al. // Heart. – 2006. – Vol. 92. – P. 1518–1519.
Svensson M. NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease / M. Svensson , A. Gorst-Rasmussen , E. B. Schmidt, K. A. Jorgensen et al. // Clin Nephrol. – 2009. - Vol. 71, № 4. – Р. 380-386.
Takami Y. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF / Y. Takami , T. Horio, Y. Iwashima , S. Takiuchi et al. // Am J Kidney Dis. – 2004. – Vol. 44 – P. 420–428.
Vickery S. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: Relationship to renal function and left ventricular hypertrophy / S. Vickery, C. P. Price, R. I. John, N. A. Abbas et al. // Am J Kidney Dis. – 2005. – Vol. 46. – P. 610–620.
Wang A. Y. M. Use of Cardiac Biomarkers in End-Stage Renal Disease/ A. Y. M. Wang, L. Kar-Neng // J Am Soc Nephrol. - 2008.- Vol. 19. – P. 1643–1652.
Weber M. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine /M. Weber, C. Hamm // Heart.- 2006. - Vol. 6, № 92. – P. 843–849.
Zoccali C. Biomarkers of Left Atrial Volume. A Longitudinal Study in Patients With End Stage Renal Disease / C. Zoccali, G. Tripepi, F. Mattace-Raso, F. Mallamaci, F. A. Benedetto et al. // Hypertension. – 2009. - № 54. – P. 818-824.
